Salovum egg yolk containing antisecretory factor as an adjunct therapy in severe cholera in adult males: a pilot study

Nur H Alam, Hasan Ashraf, Maryam Olesen, Mohammed A Salam, Niklaus Gyr, Remy Meier, Nur H Alam, Hasan Ashraf, Maryam Olesen, Mohammed A Salam, Niklaus Gyr, Remy Meier

Abstract

Cholera involves stimulation of intestinal secretory process in response to cholera toxin leading to profuse watery diarrhoea that might cause death due to dehydration unless timely rehydration therapy is initiated. Efforts to identify and test potential antisecretory agents are ongoing. Antisecretory factor (AF) is a naturally-occurring protein produced in the human secretory organs, including the intestine, with antisectory properties demonstrated in animal and human models of secretory diarrhoea. Salovum egg yolk powder contains antisecretory proteins in a much higher (500 times) concentration than that of normal hen eggs. This is achieved by feeding hens with specially-processed cereals, capable of inducing antisecretory proteins in the yolk. The aim of the study was to examine the effect of Salovum egg yolk powder containing AF in the treatment of adult cholera patients. In an open, randomized controlled trial (pilot study), 40 adult male patients with severe cholera were studied: 20 received standard treatment (oral rehydration solution, antibiotic, and usual hospital diet) plus Salovum egg yolk powder (study group) and 20 received standard treatment alone (control group). All the patients received tablet doxycycline (300 mg) once immediately after randomization. Written informed consent was obtained from each subject before enrollment. The main outcome measures were stool weight and duration of diarrhoea. The demographic and baseline clinical characteristics of the study patients were comparable between the groups. No significant differences were found in the mean stool weight, g/kg of body-weight during the first 24 hours [study vs control group, mean +/- standard deviation (SD), 218 +/- 119 vs 195 +/- 136], second 24 hours (mean +/- SD, 23 +/- 39 vs 22 +/- 34), and cumulative up to 72 hours (mean +/- SD, 245 +/- 152 vs 218 +/- 169). The duration (hours) of diarrhoea after admission in the hospital was also similar in both the groups (mean +/- SD, 33 +/- 14 vs 32 +/- 10). No adverse effect was observed. Salovum egg powder containing AF as an adjunct therapy in the treatment of severe cholera could not demonstrate any beneficial effect. Further studies with higher doses of Salovum egg yolk powder might be considered in future to establish its antisecretory effect.

Figures

Fig. 1.
Fig. 1.
Trial profile
Fig. 2.
Fig. 2.
Kaplan-Meier survival curve for duration of diarrhoea

References

    1. Benenson AS. Cholera. In: Benenson AS, editor. Con-trol of communicable diseases in man, 11th ed. New York, NY: American Public Health Association; 1970. p. 52.
    1. World Health Organization. Programme for Diarrhoeal Diseases Control . A manual for the treatment of acute diarrhoea for use by physicians and other senior health workers. Geneva: World Health Organization; 1984. p. 25.
    1. World Health Organization . The rational use of drugs in the management of acute diarrhoea in children. Geneva: World Health Organization; 1990. p. 71.
    1. Holmgren J, Lange S, Lonnroth I. Reversal of cyclic AMP-mediated intestinal secretion in mice by chlor-promazine. Gastroenterology. 1978;75:1103–8.
    1. Jacoby HI, Marshall CH. Antagonism of cholera enterotoxin by anti-inflammatory agents in the rat. Nature. 1972;235:163–5.
    1. Lonnroth I, Holmgren J, Lange S. Chlorpromazine inhibits cholera toxin-induced intestinal hypersecretion. Med Biol. 1977;55:126–9.
    1. Smith PL, Field M. In vitro antisecretory effects of trifluoperazine and other neuroleptics in rabbit and human small intestine. Gastroenterology. 1980;78:1545–53.
    1. Rabbani GH, Butler T, Bardhan PK, Islam A. Reduction of fluid-loss in cholera by nicotinic acid: a randomised controlled trial. Lancet. 1983;2:1439–42.
    1. Islam A, Bardhan PK, Islam MR, Rahman M. A randomized double blind trial of aspirin versus placebo in cholera and non-cholera diarrhoea. Trop Geogr Med. 1986;38:221–5.
    1. Rabbani GH, Butler T. Indomethacin and chloroquine fail to inhibit fluid loss in cholera. Gastroentero-logy. 1985;89:1035–7.
    1. Rabbani GH, Butler T, Knight J, Sanyal SC, Alam K. Randomized controlled trial of berberine sulphate therapy for diarrhea due to enterotoxigenic Escherichia coliVibrio cholerae. J Infect Dis. 1987;55:979–84.
    1. Molla AM, Gyr K, Bardhan PK, Molla A. Effect of intravenous somatostatin on stool output in diarrhea due to Vibrio cholerae. Gastroenterology. 1984;87:845–7.
    1. Farthing MJ. Introduction. Enkephalinase inhibition: a rational approach to antisecretory therapy for acute diarrhea. Aliment Pharmacol Ther. 1999;13(Suppl 6):1–2.
    1. Llorens C, Gacel G, Swerts JP, Pedrisot R, Fournie-Zaluski MC, Schwartz JC, et al. Rational design of enkephalinase inhibitors: substrate specificity of enkephalinase studied from inhibitory potency of various dipeptides. Biochem Biophys Res Commun. 1980;96:1710–6.
    1. Rachmilewitz D, Kermeli F, Chorev M, Selinger Z. Effect of opiates on human colonic adenylate cyclase activity. Eur J Pharmacol. 1983;93:163–73.
    1. Lange S, Lonnroth I. The antisecretory factor: synthesis, anatomical and cellular distribution, and biological action in experimental and clinical studies. Int Rev Cytol. 2001;210:39–75.
    1. Lange S, Lonnroth I. Passive transfer of protection against cholera toxin in rat intestine. FEMS Microbiol Lett. 1984;24:165–8.
    1. Lonnroth I, Lange S. Inhibition of cyclic AMP-media-ted intestinal hypersecretion by pituitary extracts from rats pretreated with cholera toxin. Med Biol. 1984;62:290–4.
    1. Lonnroth I, Lange S. A hormone-like protein from the pituitary gland inhibits intestinal hypersecretioninduced by cholera toxin. Regul Pept Suppl. 1985;4:216–8.
    1. Lonnroth T, Lange S. Purification and characterization of the antisecretory factor-A protein in the central nervous system and in the gut which inhibits intestinal hyper secretion induced by cholera toxin. Biochim Biophys Acta. 1986;883:138–44.
    1. Lange S, Lonnroth I. Bile and milk from cholera toxin treated rats contain a hormone-like factor which inhibits diarrhea induced by the toxin. Int Arch Allergy Appl Immunol. 1986;79:270–5.
    1. Lonnroth I, Martinsson K, Lange S. Evidence of protection against diarrhoea in suckling piglets by a hormone-like protein in the sow's milk. Zentralbl Veterinarmed B. 1988;35:628–35.
    1. Lonnroth I, Lange S. Intake of monosaccharides or amino acids induces pituitary gland synthesis of proteins regulating intestinal fluid transport. Biochim Biophys Acta. 1987;925:117–23.
    1. Ulgheri C, Paganini B, Rossi F. Antisecretory factor as a potential health-promoting molecule in man and animals. Nutr Res Rev. 2010;23:300–13.
    1. Lange S, Lonnroth I, Skadhauge E. Effect of the antiseretory factors in pigs. Pflugers Arch. 1987;409:328–32.
    1. Torres J, Jennische E, Lange S, Lonnroth I. Clostridium difficile toxin A induces a specific antisecretory factor which protects against intestinal mucosal damage. Gut. 1991;32:791–5.
    1. Lange S, Lonnroth I. Palm A, Hyden H. The effect of antisecretory factor on the permeability of nerve cell membrane to chloride ion. Pflugers Arch. 1987;410:648–51.
    1. Laurenius A, Wangberg B, Lange S, Jennische E, Lundgren BK, Bosaeus I. Antisecretory factor counteracts secretory diarrhoea of endocrine origin. Clin Nutr. 2003;22:549–52.
    1. Johansson E, Jennische E, Lange S, Lonnroth I. Antisecretory factor suppresses intestinal inflammation and hypersecretion. Gut. 1997;41:642–5.
    1. Bjorck S, Bosaeus I, Ek E, Jennische E, Lonnroth I, Johansson E, et al. Food induced stimulation of the antisecretory factor can improve symptoms in human inflammatory bowel disease: a sudy of a concept. Gut. 2000;46:824–9.
    1. Eriksson A, Shafazand M, Jennische E, Lange S. Effect of antisecretory factor in ulcerative colits on histological and laboratory outcome: a short period clinical trial. Scand J Gastroenterol. 2003;38:1045–9.
    1. Ericksson A, Shafazzand M, Jennische E, Lonnroth I, Lange S. Antisecretory factor-induced regression of Crohn's disease in a weak responder to conventional pharmacological treatment. Inflamm Bowel Dis. 2003;9:398–400.
    1. Lange S, Lonnroth I, Martinsson K. Concentrations of antisecretory factor in eggs and in chicken blood. Br Poult Sci. 1994;35:615–20.
    1. Lange S. Antisecretory proteins and medical food—new options for an effective treatment of inflammatory bowel disease: summary of a symposium, the Swedish National Meeting for Gastroenterologists (Seven Gastrodagarna), 26 April 2002. Stockholm: AS-FAKTORAB; 2002. Protein AF: Synthesis and biological effects; pp. 1–4.
    1. Alam NH, Ashraf H. Treatment of infectious diarrhoea in children. Paediatr Drugs. 2003;5:151–65.
    1. Zaman S, Mannan J, Lange S, Lonnroth I, Hanson LA. B 221, a medical food containing antisecretory factor reduces child diarrhoea: a placebo controlled trial. Acta Paediatr. 2007;96:1655–9.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever